Speech-Language Pathologists in Blacklick, OH Accepting Medicare

6 Speech-Language Pathologists found. Showing 1 - 6

Melissa Swartz, M.A. CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 752 Bent Oak Dr, Blacklick, OH 43004 Phone: 419-376-5559

Ayana Latham Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 797 Towler Dr, Blacklick, OH 43004 Phone: 330-309-7840

Mrs. Rebecca Adams, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 7977 Meranda Dr, Blacklick, OH 43004 Phone: 614-440-4300

Mrs. Ellen Maley Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1490 Climbing Fig Dr, Blacklick, OH 43004 Phone: 614-864-9089

Julie Nau Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 741 Redwood Valley Dr, Blacklick, OH 43004 Phone: 304-830-0607

April Hunter Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 6540 Havens Corners Rd, Blacklick, OH 43004 Phone: 614-479-1490    Fax: 614-759-5110

News Archive

A*STAR scientists discover potential target to weed out progression of cancer

Scientists at A*STAR have discovered an enzyme, Wip1 phosphatase, as a potential target to weed out the progression of cancer. Although studies in the past have revealed that this enzyme plays a critical role in regulating the budding of tumours, scientists have for the first time unearthed a mechanism for its mode of action.

ASCO 2015: Berg presents data from BPM 31510 Phase Ib trial for solid tumors

Berg, a biopharmaceutical company committed to uncovering health solutions through a data-driven, biological approach, presented clinical research from its trials using its cancer drug BPM 31510 on Phase Ib solid tumors and preclinical data on triple negative breast cancer, at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO), May 29 – June 2 in Chicago.

Antidepressants not linked to birth defects

Two research studies published in The New England Journal of Medicine found taking SSRIs (selective serotonin reuptake inhibitors), anti-depression drugs, during pregnancy did not significantly increase the overall risk for most birth defects.

Brookstone Pharmaceuticals changes its name to Acella Pharmaceuticals

Brookstone Pharmaceuticals, an emerging specialty pharmaceutical company, announced today its decision to change the name of the company to Acella Pharmaceuticals, LLC. This decision has been made to create a company image and brand that more accurately mirrors our commitment to "Accelerating the Health Care Solution" by bringing quality affordable products to customers and patients. Mark Pugh, CEO states, "As we have grown over the last few years, we have evolved into a more integrated pharmaceutical company.

Read more Medical News

› Verified 1 days ago